IDEAS home Printed from https://ideas.repec.org/a/spr/pharmo/v7y2023i5d10.1007_s41669-023-00430-1.html
   My bibliography  Save this article

Healthcare Costs at the End of Life for Patients with Non-cancer Diseases and Cancer in Denmark

Author

Listed:
  • Anne Høy Seemann Vestergaard

    (Aarhus University and Aarhus University Hospital)

  • Lars Holger Ehlers

    (Aalborg University and Aalborg University Hospital
    Nordic Institute of Health Economics)

  • Mette Asbjoern Neergaard

    (Aarhus University and Aarhus University Hospital)

  • Christian Fynbo Christiansen

    (Aarhus University and Aarhus University Hospital)

  • Jan Brink Valentin

    (Aalborg University and Aalborg University Hospital)

  • Søren Paaske Johnsen

    (Aalborg University and Aalborg University Hospital
    Aalborg University and Aalborg University Hospital)

Abstract

Objectives To examine costs of care from a healthcare sector perspective within 1 year before death in patients with non-cancer diseases and patients with cancer. Methods This nationwide registry-based study identified all Danish citizens dying from major non-cancer diseases or cancer in 2010–2016. Applying the cost-of-illness method, we included costs of somatic hospitals, including hospital-based specialist palliative care, primary care, prescription medicine and hospice expressed in 2022 euros. Costs of patients with non-cancer diseases and cancer were compared using regression analyses adjusting for sex, age, comorbidity, residential region, marital/cohabitation status and income level. Results Within 1 year before death, mean total healthcare costs were €27,185 [95% confidence interval (CI) €26,970–27,401] per patient with non-cancer disease (n = 109,723) and €51,348 (95% CI €51,098–51,597) per patient with cancer (n = 108,889). The adjusted relative total healthcare costs, i.e. the ratio of the mean costs, of patients with non-cancer diseases was 0.64 (95% CI 0.63–0.66) at 12 months before death and 0.91 (95% CI 0.90–0.92) within 30 days before death compared with patients with cancer. Mean costs of hospital-based specialist palliative care and hospice in the year leading up to death were €17 (95% CI €13–20) and €90 (95% CI €77–102) per patient with non-cancer disease but €1552 (95% CI €1506–1598) and €3411 (95% CI €3342–3480) per patient with cancer. Conclusions Within 1 year before death, total healthcare costs, mainly driven by hospital costs, were substantially lower for patients with non-cancer diseases compared with patients with cancer. Moreover, the costs of hospital-based specialist palliative care and hospice were minimal for patients with non-cancer diseases.

Suggested Citation

  • Anne Høy Seemann Vestergaard & Lars Holger Ehlers & Mette Asbjoern Neergaard & Christian Fynbo Christiansen & Jan Brink Valentin & Søren Paaske Johnsen, 2023. "Healthcare Costs at the End of Life for Patients with Non-cancer Diseases and Cancer in Denmark," PharmacoEconomics - Open, Springer, vol. 7(5), pages 751-764, September.
  • Handle: RePEc:spr:pharmo:v:7:y:2023:i:5:d:10.1007_s41669-023-00430-1
    DOI: 10.1007/s41669-023-00430-1
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s41669-023-00430-1
    File Function: Abstract
    Download Restriction: no

    File URL: https://libkey.io/10.1007/s41669-023-00430-1?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Shiell, Alan & Gerard, Karen & Donaldson, Cam, 1987. "Cost of illness studies: An aid to decision-making?," Health Policy, Elsevier, vol. 8(3), pages 317-323, December.
    2. Gielen, Birgit & Remacle, Anne & Mertens, Raf, 2010. "Patterns of health care use and expenditure during the last 6 months of life in Belgium: Differences between age categories in cancer and non-cancer patients," Health Policy, Elsevier, vol. 97(1), pages 53-61, September.
    3. Behrens, Cornelia & Henke, Klaus-Dirk, 1988. "Cost of illness studies: no aid to decision making? Reply to Shiell et al. (Health Policy, 8 (1987) 317-323)," Health Policy, Elsevier, vol. 10(2), pages 137-141, October.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Simon Wieser & Bruno Horisberger & Sara Schmidhauser & Claudia Eisenring & Urs Brügger & Andreas Ruckstuhl & Jürg Dietrich & Anne Mannion & Achim Elfering & Özgür Tamcan & Urs Müller, 2011. "Cost of low back pain in Switzerland in 2005," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 12(5), pages 455-467, October.
    2. Olena Hankivsk & Jane Friesen & Colleen Varcoe & Fiona MacPhail & Lorraine Greaves & Charmaine Spencer, 2004. "Expanding Economic Costing in Health Care: Values, Gender and Diversity," Canadian Public Policy, University of Toronto Press, vol. 30(3), pages 257-282, September.
    3. Allison Larg & John Moss, 2011. "Cost-of-Illness Studies," PharmacoEconomics, Springer, vol. 29(8), pages 653-671, August.
    4. Sophie Béjean & Hélène Sultan-Taïeb, 2005. "Modeling the economic burden of diseases imputable to stress at work," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 6(1), pages 16-23, March.
    5. Tarricone, Rosanna, 2006. "Cost-of-illness analysis: What room in health economics?," Health Policy, Elsevier, vol. 77(1), pages 51-63, June.
    6. Susie El Saadany & Douglas Coyle & Antonio Giulivi & Mohammad Afzal, 2005. "Economic burden of hepatitis C in Canada and the potential impact of prevention," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 6(2), pages 159-165, June.
    7. Lili Wang & Lei Si & Fiona Cocker & Andrew J. Palmer & Kristy Sanderson, 2018. "A Systematic Review of Cost-of-Illness Studies of Multimorbidity," Applied Health Economics and Health Policy, Springer, vol. 16(1), pages 15-29, February.
    8. Cawley, John & Meyerhoefer, Chad, 2012. "The medical care costs of obesity: An instrumental variables approach," Journal of Health Economics, Elsevier, vol. 31(1), pages 219-230.
    9. Bugge, Christoffer & Sæther, Erik Magnus & Brustugun, Odd Terje & Kristiansen, Ivar Sønbø, 2021. "Societal cost of cancer in Norway –Results of taking a broader cost perspective," Health Policy, Elsevier, vol. 125(8), pages 1100-1107.
    10. Shiell, Alan & Law, Matthew G, 2001. "The cost of hepatitis C and the cost-effectiveness of its prevention," Health Policy, Elsevier, vol. 58(2), pages 121-131, November.
    11. Belaya, Vera & Hansen, Heiko & Pinior, Beate, 2012. "Measuring The Costs Of Foodborne Diseases: A Review And Classification Of The Literature," 52nd Annual Conference, Stuttgart, Germany, September 26-28, 2012 138195, German Association of Agricultural Economists (GEWISOLA).
    12. Koopmanschap, Marc A. & Rutten, Frans F. H. & van Ineveld, B. Martin & van Roijen, Leona, 1995. "The friction cost method for measuring indirect costs of disease," Journal of Health Economics, Elsevier, vol. 14(2), pages 171-189, June.
    13. Caroline Bähler & Roland Rapold & Andri Signorell & Oliver Reich & Radoslaw Panczak & Eva Blozik, 2020. "Regional differences in healthcare costs at the end of life: an observational study using Swiss insurance claims data," International Journal of Public Health, Springer;Swiss School of Public Health (SSPH+), vol. 65(6), pages 969-979, July.
    14. Douglas Coyle, 1993. "Increasing the impact of economic evaluations on health care decision-making," Working Papers 108chedp, Centre for Health Economics, University of York.
    15. Randall M. Packard, 2009. "“Roll Back Malaria, Roll in Development”? Reassessing the Economic Burden of Malaria," Population and Development Review, The Population Council, Inc., vol. 35(1), pages 53-87, March.
    16. Cohen-Mansfield, Jiska & Skornick-Bouchbinder, Michal & Hoshen, Moshe & Brill, Shai, 2017. "The relationship between health services standardized costs and mortality is non-linear: Results from a large HMO population," Health Policy, Elsevier, vol. 121(9), pages 1008-1014.
    17. Keith Tolley;Gareth Morgan;Ray Cartwright;Rhys Williams, 1998. "Economic Aspects of Non-Hodgkin's Lymphoma," Series on Health 000436, Office of Health Economics.
    18. Caroline Bähler & Roland Rapold & Andri Signorell & Oliver Reich & Radoslaw Panczak & Eva Blozik, 0. "Regional differences in healthcare costs at the end of life: an observational study using Swiss insurance claims data," International Journal of Public Health, Springer;Swiss School of Public Health (SSPH+), vol. 0, pages 1-11.
    19. Marcello Basili & Filippo Belloc, 2015. "How To Measure The Economic Impact Of Vector-Borne Diseases At Country Level," Journal of Economic Surveys, Wiley Blackwell, vol. 29(5), pages 896-916, December.
    20. Kushneel Prakash & Sefa Awaworyi Churchill & Russell Smyth, 2022. "Petrol prices and obesity," Health Economics, John Wiley & Sons, Ltd., vol. 31(7), pages 1381-1401, July.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharmo:v:7:y:2023:i:5:d:10.1007_s41669-023-00430-1. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.